-- VELCADE third-quarter U.S. net sales increased 32% year-over-year to
$70.4 million --
-- Full-year financial guidance raised for second time in 2007 -- -- Phase III VISTA trial in newly diagnosed multiple myeloma stopped early due to positive interim analysis; sNDA filing now expected in December 2007
-- -- VELCADE listed in national compendia for use in newly diagnosed multiple
myeloma -- -- VELCADE label broadened by FDA providing further differentiation as
leading multiple myeloma therapy --
CAMBRIDGE, Mass., Nov. 1 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) today announced its financial and operational results for the third quarter of 2007. The Company raised its full-year 2007 financial guidance for the second time this year.
"Millennium delivered outstanding results for the quarter. U.S. net sales of VELCADE grew 32 percent over the same period last year as we fortified our leading position in relapsed multiple myeloma. The strength of our Phase III VISTA data clearly demonstrates that VELCADE has the potential to expand this leadership position into the front-line setting," said Deborah Dunsire, M.D., President and Chief Executive Officer, Millennium. "We are raising our full- year 2007 financial guidance for the second time this year, validating the success of our strategic initiatives to accelerate growth."
"We continue to outperform financial expectations driven by
|SOURCE Millennium Pharmaceuticals, Inc.|
Copyright©2007 PR Newswire.
All rights reserved